Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2021 Aug 2;9(11):4095–4102. doi: 10.1016/j.jaip.2021.07.044

Table 4.

Other Clinical Features

PIK3CD n=33 PIK3R1 n=7
Neurological
Developmental Delay 7 (21.2%) 1 (14.3%)
Hearing Loss 6 (18.2%) 3 (42.9%)
Seizures 6 (18.2%) None
Dysmorphic features 3 (9.1%) 1 (14.3%)
Failure to thrive 2 (6.1%) 2 (28.5%)
Atopic
Atopic Disease 24 (72.7%) 3 (42.9%)
Asthma 21 (63.6%) 1 (14.3%)
Food Allergies 6 (18.2%) None
Eczema 6 (18.2%) None
EoE/EGID 4 (12.1%) None
Pulmonary
Bronchiectasis 17 (51.5%) 1 (14.3%)
Interstitial lung disease/restrictive lung disease 3 (9.1%) 1 (14.3%)
Pneumothorax 1 (3.0%) 1 (14.3%)
Gastrointestinal
Enteropathy/Chronic diarrhea 5 (15.2%) 1 (14.3%)
Nodular Regenerative hyperplasia of the liver 4 (12.1%) None
Inflammatory Bowel Disease 3 (9.1%) None
Pancreatic Insufficiency 2 (6.1%) None
Endocrine
Adrenal insufficiency 4 (12.1%) None
Hypothyroidism 3 (9.1%) None
Cardiac
Cardiomyopathy 1 (3.0%) 1 (14.3%)
Renal/Genitourinary
Dysgerminoma 1 (3.0%) 1 (14.3%)
Other
Ehlers-Danlos 1 (3.0%) 1 (14.3%)

Neurological disease was commonly reported. 25.0% of patients carried a neurological diagnosis, including 15% with a history of seizures. 20.0% of patients were diagnosed with developmental delay, including one patient with autism. Atopic manifestations have not previously been described in the APDS cohort. 67.5% of patients had evidence of IgE-mediated allergic disease (asthma, eczema, allergic rhinitis, food allergy), which was higher in the PIK3CD cohort compared to the PIK3R1 cohort (72.7% vs 42.9%). 63.6% of patients in the PIK3CD cohort carried a diagnosis of asthma, while only one PIK3R1 patient was diagnosed with asthma.